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Abstract
Genome-wide association studies and follow-up meta-analyses in Crohn’s disease (CD) and ulcerative colitis (UC) have
recently identified 163 disease-associated loci that meet genome-wide significance for these two inflammatory bowel
diseases (IBD). These discoveries have already had a tremendous impact on our understanding of the genetic
architecture of these diseases and have directed functional studies that have revealed some of the biological
functions that are important to IBD (e.g. autophagy). Nonetheless, these loci can only explain a small proportion of
disease variance (,14% in CD and 7.5% in UC), suggesting that not only are additional loci to be found but that the
known loci may contain high effect rare risk variants that have gone undetected by GWAS. To test this, we have used
a targeted sequencing approach in 200 UC cases and 150 healthy controls (HC), all of French Canadian descent, to
study 55 genes in regions associated with UC. We performed follow-up genotyping of 42 rare non-synonymous
variants in independent case-control cohorts (totaling 14,435 UC cases and 20,204 HC). Our results confirmed
significant association to rare non-synonymous coding variants in both IL23R and CARD9, previously identified from
sequencing of CD loci, as well as identified a novel association in RNF186.W i t ht h ee x c e p t i o no fCARD9 (OR=0.39),
the rare non-synonymous variants identified were of moderate effect (OR=1.49 for RNF186 and OR=0.79 for IL23R).
RNF186 encodes a protein with a RING domain having predicted E3 ubiquitin-protein ligase activity and two
transmembrane domains. Importantly, the disease-coding variant is located in the ubiquitin ligase domain. Finally, our
results suggest that rare variants in genes identified by genome-wide association in UC are unlikely to contribute
significantly to the overall variance for the disease. Rather, these are expected to help focus functional studies of the
corresponding disease loci.
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Introduction
Inflammatory bowel diseases (IBDs) are classified as chronic
relapsing inflammatory diseases of the gastrointestinal tract. The
two major forms of IBDs are Crohn’s disease (CD, OMIM
266600) and ulcerative colitis (UC, OMIM 191390). Both genetic
and environment factors play a central role in the pathogenesis of
the inflammatory response of IBDs [1].
Recent genome-wide association (GWA) studies and meta-
analyses in IBD have shown great success, with the identification
of 163 independent IBD risk loci. While some loci were shown to
be specific to either CD or UC risk, most have been shown to
impact on both diseases, supporting earlier claims that these
diseases share genetic risk factors [2]. These recent studies have
identified important disease pathways but the common SNPs
identified, with generally modest effects, explain only 14% and
7.5% of disease variance for CD and UC, respectively [3].
Due to linkage disequilibrium in the genome and limitations of
GWAS chip designs to date, genome-wide scans typically identify
common variants that tag regions of variable sizes containing
multiple candidate genes for disease susceptibility. Although there
have been a few notable exceptions, most of the common
associated SNPs do not clearly identify causal variants, and
further studies are needed to highlight the causal gene in many
associated regions [4–6]. Sequencing of exons within associated
regions in order to identify rare variants with strong effect on
disease has been proposed as a means to help identify the causal
genes and to help explain a further portion of disease variance. We
have recently performed a pooled next-generation sequencing
study in Crohn’s disease, and identified association to novel low-
frequency and rare protein altering variants in NOD2, IL23R, and
CARD9, as well as IL18RAP, CUL2, C1orf106, PTPN22 and
MUC19 [7]. We opted to use a similar targeted pooled next-
generation sequencing approach to study UC-associated regions
from our recent meta-analysis of 3 independent genome-wide
scans for UC [8]. Using this approach we identified putative causal
variants significantly associated to UC in three of the 22 loci
examined and identified variants of interest for an additional six
loci.
Results
Sequence analyses
We selected 200 ulcerative colitis cases and 150 healthy controls
of French Canadian ancestry from among samples collected by the
NIDDK IBD Genetics Consortium. Samples were pooled in
batches of 50 cases or 50 controls and normalized in order for the
DNA pool to reflect sample allele frequencies. We targeted 55
genes from 14 UC-associated regions, as well as 7 regions
identified in CD showing nominal replication in our UC GWAS
study and an additional candidate gene (ECM1) reported in recent
literature [6,8–10]. PCR amplification primers were successfully
designed to capture a total of 508 amplicons for a total of 305 Kb
or 70% of our original target sequences. Of these 508 PCR
reactions, 472 (93%) successfully amplified in each of the 7 sample
pools and we used these to construct libraries for high-throughput
sequencing on an Illumina Genome Analyzer II. This sequencing
yielded large amounts of high-quality data for each pool, that
captured 99% of our amplified target regions (283 Kb total;
117 Kb exonic sequences) and achieved 15756median coverage
per pool (corresponding to 31.56per sample).
We used the previously described variant calling method
Syzygy, designed to accommodate pooled study designs, to
identify rare and low-frequency single nucleotide variants in our
pooled samples [7]. Syzygy detected 1590 high confidence variants
in our target regions, including 309 coding region variants (189
missense, 114 synonymous, 2 nonsense and 4 essential splice
Author Summary
Genetic studies of common diseases have seen tremen-
dous progress in the last half-decade primarily due to
recent technologies that enable a systematic examination
of genetic markers across the entire genome in large
numbers of patients and healthy controls. The studies,
while identifying genomic regions that influence a
person’s risk for developing disease, often do not pinpoint
the actual gene or gene variants that account for this risk
(called a causal gene/variant). A prime example of this can
be seen with the 163 genetic risk factors that have recently
been associated with the chronic inflammatory bowel
diseases known as Crohn’s disease and ulcerative colitis.
For less than a handful of these 163 is the causative
change in the genetic code known. The current study used
an approach to directly look at the genetic code for a
subset of these and identified a causative change in the
genetic code for eight risk factors for ulcerative colitis. This
finding is particularly important because it directs biolog-
ical studies to understand the mechanisms that lead to this
chronic life-long inflammatory disease.
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version 132, a non-synonymous/synonymous ratio of 1.7 and a
transition/transversion ratio of 2.38 (Table S1). These results are
similar to those obtained from our recent re-sequencing study in
CD, as well as those reported by the 1000 Genomes Project, and
are indicative of a relatively high true-positive rate for our dataset.
This was confirmed by genotyping the 350 discovery DNA
samples for a random subset of 237 variants from the total of 1590
high quality variants (Table S2).
Follow-up genotyping and association analyses
After removal of variants that did not validate, variants
observed only once in our sequencing dataset (singletons) and
variants from the MHC region, 84 non-synonymous coding
variants (missense, non-sense and splicing variants), were used for
subsequent analyses. Following removal of common variants
(frequency .5%) and variants that did not design in our
genotyping assays, we carried out follow-up genotyping for 42 of
these variants. Genotyping was performed in 6 independent case-
control cohorts totaling 7,292 UC cases and 8,018 HC (Table S3),
and additional data was obtained for 7,143 UC cases and 12,186
HC from the International IBD Genetics Consortium (IIBDGC)
Immunochip project for 14 of these variants [3].
Since our study focuses on infrequent and rare variants, we
expect few non-reference alleles for these variants in each
subcohort studied, which precludes the use of asymptotic statistics
utilized in typical association studies of common variants. Also,
given the low frequencies of the variants tested, population
structure is likely to be a more substantial problem and thus
requires a stratified analysis with strict population case-control
matching. We used a previously described mega-analysis of rare
variants (MARV) approach that provides a permutation-based
estimate of significance, within each sub-cohort, and accommo-
dates variable numbers of case-control samples in each indepen-
dent population for single-marker analysis [7].
With a target set of 42 variants we can define a traditional
corrected significance level of P=0.0012 for our study. Three
variants, located in the CARD9, IL23R and RNF186 genes, reach
this significance threshold suggesting that these could possibly be
the causal genes/variants within these two loci (Table 1).
Specifically, our results show that the c.IVS11+1G.C CARD9
splice variant confers significant protection to UC
(P=1.47610
211; OR=0.39 [0.30–0.53]). We previously identi-
fied this splice variant in a sequencing project of CD loci and
demonstrated that it leads to an alternatively spliced transcript that
is missing exon 11 [7]. Our results also identify significant
association to the valine to isoleucine substitution at position 362
(Val362Ile) in IL23R (P=1.18610
203; OR=0.79 [0.68–0.91])
previously reported by a recent re-sequencing of positional
candidates in Crohn’s disease [7,11]. The significantly associated
rare variant that we identified in RNF186 (P=8.69610
24;
OR=1.49 [1.17–1.90]) encodes an alanine to threonine substitu-
tion at position 64 (Ala64Thr). RNF186 encodes a protein with a
RING domain and two transmembrane domains. Importantly, the
disease-coding variant is located in the RING domain, a domain
with a predicted E3 ubiquitin-protein ligase activity (Fig. 1).
Independence of effect between rare variants in IL23R and
CARD9 and the reported common association signals in these
genes has previously been shown [7,11]. For RNF186, the
Ala64Thr variant is mostly found on the protective haplotype
background from the previously identified common variant,
indicating that the reported association is not likely due to partial
LD with the common variant. In addition, reciprocal conditional
logistic regression analysis, using a subset of samples where both
variants were genotyped (3548 UC cases and 3607 healthy
controls) shows that these are independent association signals (data
not shown).
Given the challenge inherent in achieving corrected significance
thresholds for rare variants, even with large cohorts, we expect
that some of the other variants that we identified and found to
have nominal significance (0.0012,P,0.05) are truly associated
with UC. In fact with a target set of 42 variants included in follow-
up genotyping, and supposing these are independent and under
the null, we would expect ,1 SNP to exceed P,0.01 (with a
probability of less than 1% to observe 3 or more associations at this
level) and ,2 SNPs to exceed P,0.05 by chance alone (with a
probability less than 0.0001 to observe 9 or more association at
this level), whereas we observe 3 SNPs with P,0.01 and 9 SNPs
with P,0.05, suggesting that there are additional true positives
that have not met the more stringent threshold. Indeed, within the
group of SNPs that we found to have nominal significance are two
non-synonymous coding variants (Gly149Arg and Val362Ile) in
IL23R that we and others have shown to be associated with
protection from IBD (Table 1) [7,11]. In addition to these
previously-validated variants in IL23R, we have found variants
that are nominally associated with UC in the genes encoding
CEP72, LAMB1, CCR6, JAK2, and STAC2 (Table 1). Specifically,
we identified two nominally associated rare variants in CEP72
(Lys314Arg and Asp316Asn) in perfect LD with each other that
appear to protect from UC (Table 1). As we also sequenced the
only other gene in this locus (TPPP), but did not find any
associated variants in it, this suggests that CEP72 is potentially
causal. Similarly, we sequenced both genes in the LAMB1-DLD
locus on chromosome 7, with the nominally associated rare variant
in LAMB1 (Ile154Thr) suggesting a role for this gene in risk to UC,
especially as the associated allele is located in its DUF287 domain
and is predicted to have a damaging effect [12]. All genes within
the CCR6-FGFR1OP-RNASET2 locus were sequenced, with a
single nominally-associated variant (Ala369Val) in CCR6, consis-
tent with this gene’s probable role in the migration and
recruitment of dendritic and T cells during inflammatory and
immunological responses [13]. Within the JAK2-INSL6-LHX3
locus, we only sequenced JAK2 given its key role in signaling from
the IL12R/IL23R, a biological pathway proven to be associated
with IBD, and identified a nominally associated variant (Ar-
g1063His) within its catalytic domain. STAC2 is within a locus with
16 other genes including ORMDL3, which has been suggested to
be the most likely causal gene based previous genetic and
functional studies in IBD and asthma [8,14]. Although we find a
nominally associated variant in STAC2 (Lys302Arg) and none in
ORMDL3, we have only sequenced 10 of the 17 genes within this
locus (Table S4). Studies of each of these variants to determine
their functional impact will be essential to prove causality.
Discussion
Genome-wide association studies in IBD have been very
successful in identifying genomic regions associated with CD,
UC or both. Only infrequently have these GWA studies also
directly identified the causal genes/variants, with NOD2, IL23R
and ATG16L1 being the few known examples. A recent targeted
(exons and exon-intron boundaries) sequencing approach of
known CD loci resulted in the identification of potentially causal
variants in eight of the 36 loci examined [7]. The primary
objective of the current study therefore was to use the same
approach to identify likely causal variants within genes that were
located in genomic regions associated with UC. While there are
over 100 UC loci that have been identified and validated to date,
Deep Resequencing of GWAS Loci in UC
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initiation of this project. Of these 22 loci, the current study
identified potentially causal variation in three of the loci: two
protective alleles in CARD9 and IL23R, and an allele increasing
risk in RNF186.
The identification of a rare variant (Ala64Thr) in RNF186 that
shows significant association to UC strongly suggests that this is the
causal gene within this locus. Importantly, the disease-coding
variant is located in the RING domain, a domain with a predicted
E3 ubiquitin-protein ligase activity. Ubiquitin ligases have been
shown to regulate key adaptors of proinflammatory pathways [15–
17]. We previously reported that RNF186 expression was higher in
human intestinal tissues than in immune tissues [8]. We showed by
immunostaining that the RNF186 protein was expressed at the
basal pole of epithelial cells and lamina propria within colonic
tissues. Using GEO public microarray datasets, we pursued a
systematic follow-up analysis of expression profiles of epithelial
cells in response to bacterial products, PAMPs/pathogens. We
found that RNF186 gene expression was significantly up-regulated
in small intestine epithelium and induced by Shigella infection in
mice (P=4.21610
28) (Figure 1, Panel A) [18,19]. Both invasive
(INV+) and non-invasive (INV2) strains of Shigella induced
significant overexpression of RNF186 in intestinal tissues of 4-day-
and 7-day-old mice infected for 2 or 4 hours. To further identify
putative transcriptional regulators of RNF186 expression, we
employed a text-mining and network-generating analysis of
human protein-protein, protein-DNA, protein-RNA and protein-
compound interactions. Specifically, from our analyses we
Figure 1. Functional characterization of RNF186. (A) RNF186 encodes a protein with RING domain and two transmembrane domains. E3
ubiquitin-protein ligase activity is intrinsic to the RING domain. This domain contains the disease-coding variant (A64T). (B) RNF186 expression
response to S. flexneri in young mice (see also Figure S11). (C) Network building steps. Network is generated by mining multiple sources of interaction
databases in Metacore that span human protein-protein, protein-DNA, Protein-RNA and protein-compounds interactions. (D) Transcriptional
regulation model for RNF186. IL1-beta and TGF-beta 1 decrease HNF4A mRNA expression [39–41]. Knockdown of retinoid X receptor, alpha (RXRA)
down-regulates HNF4A gene expression; RXRA interacts with HNF4A gene [24]. HNF4A is a direct target gene of caudal type homeobox 2 (CDX2);
CDX2 increases HNF4A mRNA expression in intestinal epithelial cells [42,43]. HNF4A binds promoter region of HNF1A and up-regulates its expression.
HNF1A interacts with RNF186 and regulates its transcription.
doi:10.1371/journal.pgen.1003723.g001
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step process by the transcription factor Hepatocyte Nuclear
Factor 4, alpha (HNF4A) (Figure 1, Panels B,C). Several studies
have shown that HNF4A binds to the promoter region and up-
regulates the expression of yet another transcription factor
HNF1A [20–22]. Knockdown of HNF4A has been shown to
down-regulate HNF1A gene expression [23,24]. HNF1A, in
turn, regulates RNF186 and this interaction has been confirmed
by chromatin immunoprecipitation and chip-on-chip assay [25–
27]. Our own analysis of transcriptional profiles of HNF4A-Null
colons recovered from HNF4A
loxP/loxPFoxa3Cre and HNF4A-
loxP/2Foxa3Cre mice uncovered a significant up-regulation of
RNF186 transcript [28]. Expression profiling of human tissues
also supports this hypothesis, as HNF4A and RNF186 are clearly
co-expressed in the small intesti n ea n dt h ec o l o n( F i g u r eS 1 ) .
This putative interaction is particularly relevant given that
HNF4A has previously been shown to be associated, with
genome-wide significance, with risk to developing UC [9]. Our
analysis now indicates a direct genetic interaction between two
IBD susceptibility genes namely, HNF4A and RNF186.W h i l ea
singular loss-of-function mutation in HNF4A has already been
shown to be associated with susceptibility to abnormal intestinal
permeability, inflammation and oxidative stress, we speculate
that a dual loss-of-function with additional mutation in RNF186
would further exacerbate one’s susceptibility to develop chronic
inflammation in the gut [29,30].
In addition to the variants in IL23R, CARD9, and RNF186,w e
also identified variants of interest in an additional five loci
(specifically within the CEP72, LAMB1, CCR6, JAK2, and STAC2
genes). While these latter six still require confirmation, we estimate
that many will validate given that we observed an excess of
nominally-associated variants. Examining the data from the
current study along with the data derived from prior association
and sequencing studies suggests that at a minimum, there
currently is strong evidence of association to causal variation in
IBD (i.e. missense, nonsense or splice junction variants) in the
NOD2, ATG16L1, IL23R, MST1, CARD9, IL18RAP and RNF186
genes, and at least suggestive evidence for causal variation in the
CUL2, C1orf106, PTPN22, MUC19, CEP72, LAMB1, CCR6, JAK2,
and STAC2 genes (Current study and references [4,5,7,11,31]).
While only a small fraction of the recently identified 163 IBD loci
have been sequenced (36 CD, 22 UC for total of 42 independent
Table 1. Identification of rare variants associated with ulcerative colitis.
Follow-up genotyping IIBDGC Immunochip data Combined
Gene, mutation alleles tested, alleles tested, alleles tested
chromosome: position
a allele frequency
c allele frequency
c
UC HC P UC HC P UC HC OR (95% CI) P
RNF186, p.Ala64Thr 14580 16034 8.69E-04 NA NA NA 14580 16034 1.49 8.69E-04
1: 20013992 1.21% 0.69% (1.17–1.90)
IL23R, p.Gly149Arg
b 14472 15936 0.097 14262 24346 0.197 28734 40282 0.74 0.032
1: 67421184 0.25% 0.35% 0.34% 0.44% (0.56–0.97)
IL23R, p.Val362Ile
b 14566 16026 0.025 11182 21102 0.024 25748 37128 0.79 1.18E-03
1: 67478488 1.27% 1.52% 1.17% 1.48% (0.68–0.91)
CEP72, p.Lys314Arg 10278 10534 0.012 NA NA NA 10278 10534 0.17 0.012
5: 690668 0% 0.095% (0.036–0.79)
CEP72, p.Asp316Asn 14558 16034 0.043 NA NA NA 14558 16034 0.34 0.043
5: 690673 0.021% 0.075% (0.12–1.00)
CCR6, p.Ala369Val 13378 14454 4.52E-04 11180 21098 0.71 24560 35552 1.26 0.013
6: 167470814 0.99% 0.66% 0.84% 0.82% (1.05–1.51)
LAMB1, p.Ile1547Thr 13374 14450 0.018 11170 21090 0.159 27432 35540 1.16 0.017
7: 107357198 2.03% 1.61% 2.39% 2.10% (1.03–1.30)
JAK2, p.Arg1063His 14528 15976 0.015 NA NA NA 14528 15976 0.65 0.015
9: 5116343 0.34% 0.58% (0.45–0.92)
CARD9, c.IVS11+1G.C
b 7002 7146 1.21E-06 14286 24362 1.81E-06 21290 31508 0.39 1.47E-11
9: 138379413 0.31% 0.99% 0.28% 0.71% (0.30–0.53)
STAC2, p.Lys302Arg 14580 16036 0.038 NA NA NA 14580 16036 1.39 0.038
17: 34624048 0.62% 0.47% (1.02–1.90)
aPositions from Human genome build 36.
bPreviously reported variant independently identified in the current study.
cMinor allele frequencies estimates from combined case:control cohorts; actual allele frequencies can vary between cohorts.
UC, Ulcerative Colitis; HC, Healthy Controls; NA, data not available.
doi:10.1371/journal.pgen.1003723.t001
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,10% (15 of 163 total loci) to ,35% (15 of 42 loci sequenced) of
IBD loci have causal variation affecting the protein-coding or
splice junctions. There are an additional 5 loci (ITLN1, GSDMB,
YDGL, SLC22A4, and FCGR2A) for which there are non-
synonymous coding or splice variants present in public databases
(dbSNP, 1KG) that are correlated with the index SNP identified in
the GWA studies that have yet been tested directly, thus
potentially increasing the estimated number of IBD loci with
causal variation within the coding and splice regions [3,32].
Furthermore, it should be noted that with the exception of a
small number of variants with significant effect (e.g. R702W,
G908R, fs107insC in NOD2; R381Q in IL23R; IVS11+1G.C
in CARD9; V527L in IL18RAP – all of which had 0.5.OR.2)
most of the rare variants identified by targeted sequencing of
loci from GWAS regions have relatively modest effect sizes that
are comparable to those observed for the common variants
identified by GWA studies. Consequently, very large sample
sizes are required to detect statistically significant association. In
the current study, for the majority (93%) of variants with an
observed minor allele frequency greater than 0.3%, we had
more than 80% power to detect significant association if the OR
is 2 or greater with the number of samples typed (up to ,14,000
cases and ,20,000 controls) (see Table S5). Moreover, should
this observation not be limited to risk loci identified by GWA
studies, this has implications with respect to future efforts for
discovering risk loci. Specifically, if the occurrence of rare
variants with large effects sizes is relatively infrequent, then this
may favor the current paradigm of locus discovery by GWA
followed by targeted sequencing rather than whole-exome or
whole-genome sequencing for locus discovery as this would
require even larger sample sizes. Alternatively, given the ever-
growing size of public databases of common and rare variants,
targeted genotyping of known variants within risk loci identified
by GWA may prove to be an efficient approach. For example,
all but two of the 22 candidate causal variants identified in the
current study or that of Rivas and colleagues are now found in
the Exome Sequencing Project database.
Regardless of the study design, these results suggest that a
significant proportion of IBD loci contain causal variants within
exons or exon-intron boundaries. While these rare/infrequent
variants may not account for what has been termed ‘‘the missing
heritability’’ of common traits, discovering these variants
certainly can provide focus for follow-up functional studies.
For example, the current sequencing and follow-up genotyping
of the chromosome 1p36 locus, which was first identified in a
GWA study of UC, identified significant association to the
Ala64Thr variant within RNF186. While further studies will be
required, the initial bioinformatics and experimental studies
described above suggest that this ring finger protein with an
ubiquitin-ligase domain may have an important role in the
response to microbes/microbial products. Going forward,
systematic evaluation of genes within risk loci via expression-
driven functional studies in cellular models (i.e. knock-down or
over expression) with sensitive high throughput/high content
r e a d o u t sm a yv e r yw e l lb eac o m p l e m e n t a r ya p p r o a c hg i v e n
t h a ta tl e a s tat h i r do fI B Dr i s kl o c ia p p e a rt oa c tv i ag e n e
expression [3].
Materials and Methods
DNA preparation and pooling
We selected 200 ulcerative colitis patients and 150 healthy
control of French-Canadian descent from the NIDDK IBD
Genetics Consortium repository samples. The NIDDK IBDGC
samples were collected under rigorous clinical phenotyping and
control matching for the purpose of genetic studies [33]. Genomic
DNA concentrations were measured by Quant-iT PicoGreen
dsDNA reagent (Invitrogen) and detected on the Biotek Synergy 2
plate reader. All DNAs were normalized with at least two round of
dilution and quantification down to a concentration of 10 ng/mla s
described previously [7]. Equimolar amounts of samples were
pooled together in batches of 50 cases and 50 controls for a total of
7 pooled groups.
Target selection and design
Target exonic sequences were selected based on the coding
exons of 55 genes in 14 UC-associated regions and 7 regions
identified in CD with nominal replication in our recent UC GWAS
study, as well ECM1 identified from recent candidate-gene study in
UC [6,8–10,34]. Specifically, amplicons were designed from
genome build Hg18 using a web-base automated pipeline (Optimus
primer: Website (http://op.pgx.ca)) that uses the Primer 3 design
software and user defined parameters [35]. Design parameters
included amplicon sizes between 400 and 600 base pairs, as well as
the inclusion of Not1 tails for subsequent concatenation and
shearing steps in library construction. PCR amplification reactions
contained 40 ng of pooled genomic DNA, 16 HotStar buffer,
0.8 mM dNTPs, 2 mM MgCl2, 0.4 units of HotStar Enzyme
(Qiagen), and 0.25 mM forward and reverse primers in a 10-ml
reaction volume. PCR cycling parameters were as follows: one
cycle of 95uC for 5 min; 30 or 35 cycles of 94uC for 30 s, 60uC for
30 s, and 72uC for 1 min; followed by one cycle of 72uC for 5 min.
Each DNA pools were amplified for 508 PCR reactions;
amplification products were then dosed by Quant-iT PicoGreen
dsDNA reagent (Invitrogen) quantification and amplification
specificity was validated by agarose gel electrophoresis. In total,
472 PCR amplicons (93% amplification success rate, capturing
283 Kb including 117 Kb of target exonic sequences) (Table S6)
for each DNA pool were combined in equimolar amounts to obtain
equal representation of all target in library construction.
Sequencing and variant discovery
The combined PCR products from each pooled DNA group
were concatenated using the NotI adapters and sheared into
fragments as previously described [36]. Libraries were constructed
according to Illumina single-end library protocol, with 150–
200 bp gel size selection and PCR enrichment using 10 cycles of
PCR, and then single-end sequenced with 36 cycles on an Illumina
Genome Analyzer II. Each sample pool was sequenced using a
single lane of Illumina GAII analyzer flowcell; 36-base pair reads
were aligned to the genome using MAQ algorithm [37] and base
qualities were recalibrated using GATK (Genome Analysis
ToolKit) [38]. Finally, variant discovery was performed using
the previously described Syzygy software, designed to analyze
sequencing data from pooled DNA sequencing [7].
Genotyping, validation and follow-up genotyping
We randomly selected 237 high quality variants for validation in
our 350 discovery DNAs samples using Sequenom MassARRAY
iPlex200 chemistry. Genotyping assay designs were obtained from
the Assay Designer v.3.1 software, and genotyping oligonucleo-
tides were synthesized at Integrated DNA Technologies. The
correlation coefficient between observed minor allele frequencies
and frequencies estimated from Syzygy for validated variants was
calculated in order to evaluate the overall quality of our dataset
(Figure S2). Eighty-four high quality non-synonymous coding
variants (missense, nonsense and splicing variants (within 2 bp of a
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sequencing results, variants that did not validate and variants
within the MHC region. We then evaluated these variants in an
independent cohort of North-American individual of European
descent from the NIDDK IBD genetics consortium (754 cases and
1008 controls); only variants detected in this independent cohort
were kept for follow-up genotyping. Following assay design, 42
SNPs were genotyped using Sequenom MassARRAY iPlex200
chemistry in 6 independent follow-up case-control cohorts (7292
cases and 8018 controls) (Table S3). Because of design constraints
and assay failures, not all markers were examined in all follow-up
sample sets. For a subset of these variants, further genotyping data
was obtained from the International IBD Genetics Consortium
Immunochip data (7143 UC, 12186 controls)
Cohort descriptions
For all cohorts, UC was diagnosed according to accepted
clinical, endoscopic, radiological and histological findings.
Genotyping of the NIDDK IBDGC cohort, as well as the
Italian and Dutch cohorts was performed at the Laboratory for
Genetics and Genomic Medicine of Inflammation (www.
inflammgen.org) of the Universite ´ de Montre ´al.
NIDDK IBD Genetics Consortium (IBDGC) samples were
recruited by the centers included in the NIDDK IBDGC: Cedars
Sinai, Johns Hopkins University, University of Chicago and Yale,
University of Montreal, University of Pittsburgh and University of
Toronto. Additional samples were obtained from the Queensland
Institute for Medical Research, Emory University and the
University of Utah. Medical history was collected with standard-
ized NIDDK IBDGC phenotype forms. Healthy controls are
defined as those with no personal or family history of IBD.
The Italian samples were collected at the S. Giovanni Rotondo
‘‘CSS’’ (SGRC) Hospital in Italy.
The Dutch cohortis composedofulcerativecolitiscasesrecruited
through the Inflammatory Bowel Disease unit of the University
Medical Center Groningen (Groningen), the Academic Medical
Center (Amsterdam), the Leiden University Medical Center
(Leiden) and the Radboud University Medical Center (Nijmegen),
and of healthy controls (n=804) of self-declared European ancestry
from volunteers at the University Medical Center (Utrecht).
Genotyping of the German cohort was performed at the
Institute for Clinical Molecular Biology
Christian-Albrechts-University in Kiel. German patients were
recruited either at the Department of General Internal Medicine
of the Christian-Albrechts-University Kiel, the Charite ´ University
Hospital Berlin, through local outpatient services, or nationwide
with the support of the German Crohn and Colitis Foundation.
German healthy control individuals were obtained from the
popgen biobank.
Genotyping of Swedish UC cases and controls was performed at
Karolinska Institutet’s Mutational Analysis core facility (MAF).
Swedish ulcerative colitis patients and controls were recruited at
the Karolinska University Hospital, Stockholm, and at the O ¨ rebro
University Hospital, O ¨ rebro, Sweden.
Genotyping of the Belgian cohort was performed at the
Genomics Core Facility at UZ Leuven, using a MassARRAY
iPLEX (Sequenom). Belgian patients were all recruited at the IBD
unit of the University Hospital Leuven, Belgium; control samples
are all unrelated, and without family history of IBD or other
immune related disorders.
Ethics statement
All patients and control subjects provided informed consent.
Recruitment protocols and consent forms were approved by
Institutional Review Boards at each participating institutions. All
DNA samples and data in this study were denominalized.
Association analysis
Association analysis of follow-up genotyping data was per-
formed using the previously described mega-analysis of rare
variants (MARV) approach [7]. Briefly, this method evaluates
significance of association from stratified sample, using within sub-
cohort permutation of individual phenotypes to provide the test
statistic. This approach is robust to population stratification and to
deviation from Hardy-Weinburg equilibrium.
Network analyses
We downloaded and analyzed several Gene Expression
Omnibus (GEO) public microarray datasets including: (a)
Expression data from newborn mice infected with Shigella
flexneri; GSE9785 (b) Transcription profiles of colon biopsies
from UC patients and healthy controls; GSE11223 (c) Steady-
state gene expression data of Tuberculosis infected human
primary dendritic cells; GSE34151 (d) PBMC transcriptional
profiles in healthy subjects, patients with Crohn’s Disease, and
patients with Ulcerative Colitis; GSE3365, (e) Transcription
profiles of colon biopsies from Crohn’s patients and healthy
controls; GSE20881, (f) Transcription profile of mouse small
intestine epithelium vs. mesenchyme; GSE6383, (g) Gene
expression in HNF4 null mouse colons compared to control
colons; GSE3116, and (h) Microarray profiles of mouse
epithelial colon harboring conditional knock out of HFN4A;
GSE11759. Each of these datasets was normalized using
quantile normalization routinei nM A T L A B .G e n e sw e r et e s t e d
for significant differences between pairs of control and
stimulated/treated samples within each experiment. After
selecting genes with nominal P,0.05, estimated using an
unpaired T-test, expression of RNF186 was evaluated whether
it passed the significance threshold or not. The results of
processing all these datasets ares h o w ni nT a b l eS 7a n dF i g u r e s
S 3 ,S 4 ,S 5 ,S 6 ,S 7 ,S 8 ,S 9 ,S 1 0 ,S 1 1 ,S 1 2 ,S 1 3 ,S 1 4 .F o r
transcriptional network analysis, we used Metacore’s suite of
network building algorithms to expand the sub-network around
RNF186. The algorithm searches through a manually curated
knowledgebase of molecular interaction to identify bidirectional
connectivity with genes, proteins and small molecules. The
search was constrained to expand the overall network size up to
50 components. Given that the bioinformatic analyses suggested
that HNF4A controlled the expression of RNF186,w ed i r e c t l y
tested for their co-expression in a panel of RNAs from a variety
of human tissues. Specifically, expression levels of RNF186 and
HNF4A were evaluated using a custom expression array from
Agilent, which was designed to include an independent probe
for each exon of the genes tested (Figure S1). Briefly, total RNA
from bone marrow, heart, skeletal muscle, uterus, liver, fetal
liver, spleen, thymus, thyroid, prostate, brain, lung, small
intestine and colon were purchased from Clontech Laboratories.
Ar e f e r e n c eR N As a m p l ew a sa l s oincluded that consisted of an
equal mix from 10 different human tissues (adrenal gland,
cerebellum, whole brain, heart, liver, prostate, spleen, thymus,
colon, bone marrow). With the exception of the small intestine
(RIN=7.6), all RNAs had a RNA Integrity Value (RIN) value
$8 (range 8.0–9.3) as measured by Agilent 2100 Bioanalyzer
using the RNA Nano 6000 kit (Agilent Technologies). Labeled
cRNA was then synthesized from 50 ng of each RNA sample
using the Low Input Quick Amp WT labeling kit (Agilent
Technologies) according to the manufacturer’s protocol. Quan-
tity and quality of labeled cRNA samples were assessed by
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was performed according to the manufacturer’s standard
protocol and microarrays were scanned using the Sure Scan
Microarray Scanner (Agilent technologies). An expression value
was obtained for each gene in each replicate by calculating the
geometric mean of all probes within the gene, followed by a
median normalization across all genes on the array. A geometric
mean and geometric standard deviation was calculated from at
least 3 independent measurements for each tissue.
Supporting Information
Figure S1 RNF186 and HNF4A are co-expressed in human
intestinal tissues. Expression levels of (A) RNF186 and (B) HNF4A
were evaluated in a panel of human tissues (bone marrow (Bone
M.), heart, skeletal muscle (Sk.Muscle), uterus, liver, fetal liver
(F.Liver), spleen, thymus, thyroid, prostate, brain, lung, small
intestine (Small I.) and colon) and shown to be co-expressed in
small intestine and colon, but show differential expression in liver.
Intensity values for each tissue represent the geometric mean with
geometric standard deviation of 3 independent measurements;
each measurement represents the geometric mean of all probes
(one per exon) for each gene followed by a median normalization
across all genes on the array. The dotted line indicates the
threshold level for detection of basal expression. The reference
sample (Ref.) is composed of a mixture RNAs derived from 10
different human tissues.
(TIFF)
Figure S2 Correlation between minor allele frequencies estimat-
ed from sequence and genotype data. Minor allele frequency
correlation between Syzygy estimates and genotyped data in
discovery samples for 179 non-monomorphic variants from the
237 randomly selected set of high quality variant. (A) Whole range
of minor allele frequencies shown. (B) Infrequent allele frequencies
only (minor allele frequency #0.05). In this experiment, correlation
gets lower as minor allele frequency threshold increase (R
2=0.88,
0.75, 0.59, 0.57 and 0.19 for MAF$0, 0.05, 0.10, 0.20 and 0.30,
respectively). This reflects the increase in absolute error for variants
with greater MAF (funnel shaped plot), and is consistent with the
higher validation rate for low-frequency variants (Table S2).
(TIFF)
Figure S3 Comparative gene expression profiling in PBMC
from healthy subjects and patients with ulcerative colitis (UC). (A)
Table of gene expression fold change statistics from comparison of
PBMC transcriptional profiles in healthy subjects and patients
with ulcerative colitis (UC) (GSE3365). Only top 10 genes and
RNF186 are shown. The rank column refers to the rank of the
gene for signal to noise ratio in the specific study (1061 significant
genes ranked). (B) Plot of RNF186 gene expression in samples from
normal individuals and patients with UC. The squares and crosses
represent median and mean respectively.
(TIFF)
Figure S4 Comparative gene expression profiling in PBMC
from healthy subjects and Crohn’s disease patients. (A) Table of
gene expression fold change statistics from comparison of PBMC
transcriptional profiles in healthy subjects and Crohn’s disease
patients (GSE3365). Only top 10 genes and RNF186 are shown.
The rank column refers to the rank of the gene for signal to noise
ratio in the specific study (1844 significant genes ranked). (B) Plot
of RNF186 gene expression in samples from normal individuals
and Crohn’s disease patients. The squares and crosses represent
median and mean respectively.
(TIFF)
Figure S5 Comparative gene expression profiling in colon
epithelial biopsies from ulcerative colitis patients and healthy
control donors. (A) Table of gene expression fold change statistics
from transcriptional profiling of colon epithelial biopsies from
ulcerative colitis patients and healthy control donors (GSE11223).
Only top 10 genes and RNF186 are shown. The rank column
refers to the rank of the gene for signal to noise ratio in the specific
study (1214 significant genes ranked). (B) Plot of RNF186 gene
expression in samples from Non-inflamed control colon and
inflamed colon. The squares and crosses represent median and
mean respectively.
(TIFF)
Figure S6 Comparative gene expression profiling of endoscopic
biopsies taken at ileocolonoscopy from ascending colon of Crohn’s
disease patients and healthy control donors. (A) Table of gene
expression fold change statistics from transcriptional profiling of
endoscopic biopsies taken at ileocolonoscopy from ascending colon
of Crohn’s disease patients and healthy control donors
(GSE20881). Only top 10 genes and RNF186 are shown. The
rank column refers to the rank of the gene for signal to noise ratio in
the specific study (2510 significant genes ranked). (B) Plot of
RNF186 gene expression in samples from ascending colon biopsies
of normal subjects and Crohn’s disease patients. The squares and
crosses represent median and mean respectively.
(TIFF)
Figure S7 Comparative gene expression profiling of endoscopic
biopsies taken at ileocolonoscopy from descending colon of
Crohn’s disease patients and healthy control donors. (A) Table
of gene expression fold change statistics from transcriptional
profiling of endoscopic biopsies taken at ileocolonoscopy
from descending colon of Crohn’s disease patients and healthy
control donors (GSE20881). Only top 10 genes and RNF186
are shown. The rank column refers to the rank of the gene for
signal to noise ratio in the specific study (579 significant genes
ranked). (B) Plot of RNF186 gene expression in samples from
descending colon biopsies of normal subjects and Crohn’s disease
patients. The squares and crosses represent median and mean
respectively.
(TIFF)
Figure S8 Comparative gene expression profiling of endoscopic
biopsies taken at ileocolonoscopy from sigmoid colon of Crohn’s
disease patients and healthy control donors. (A) Table of gene
expression fold change statistics from transcriptional profiling of
endoscopic biopsies taken at ileocolonoscopy from sigmoid colon
of Crohn’s disease patients and healthy control donors
(GSE20881). Only top 10 genes and RNF186 are shown. The
rank column refers to the rank of the gene for signal to noise ratio
in the specific study (613 significant genes ranked). (B) Plot of
RNF186 gene expression in samples from sigmoid colon biopsies of
normal subjects and Crohn’s disease patients. The squares and
crosses represent median and mean respectively.
(TIFF)
Figure S9 Comparative gene expression profiling of endoscopic
biopsies taken at ileocolonoscopy from terminal ileum of Crohn’s
disease patients and healthy control donors. (A) Table of gene
expression fold change statistics from transcriptional profiling of
endoscopic biopsies taken at ileocolonoscopy from terminal ileum
of Crohn’s disease patients and healthy control donors
(GSE20881). Only top 10 genes and RNF186 are shown. The
rank column refers to the rank of the gene for signal to noise ratio
in the specific study (2608 significant genes ranked). (B) Plot of
RNF186 gene expression in samples from terminal ileum biopsies
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crosses represent median and mean respectively.
(TIFF)
Figure S10 Comparative gene expression profiling of murine
small intestinal epithelium and mesenchyme. A) Table of gene
expression fold change statistics from transcriptional profiling of
murine small intestinal epithelium and mesenchyme (GSE6383).
Only top 10 genes and RNF186 are shown. The rank column
refers to the rank of the gene for signal to noise ratio in the specific
study (7239 significant genes ranked). (B) Plot of RNF186 gene
expression in samples from murine small intestinal epithelium and
mesenchyme. The squares and crosses represent median and
mean respectively.
(TIFF)
Figure S11 Comparative gene expression profiling of intestinal
tissues of 4-day- or 7-day-old mice infected or not with invasive or
non-invasive shigella. (A) Table of gene expression fold change
statistics from transcriptional profiling of intestinal tissues of 4-day-
or 7-day-old mice infected or not with invasive (INV+) or non-
invasive (INV2) (GSE9785). Only top 10 genes and RNF186 are
shown. The rank column refers to the rank of the gene for signal to
noise ratio in the specific study (2258 significant genes ranked). (B)
Plot of RNF186 gene expression in mice intestinal tissue infected
with shigella and control samples. The squares and crosses
represent median and mean respectively.
(TIFF)
Figure S12 Comparative gene expression profiling in primary
dendritic cells from 65 individuals, before and after infection with
MTB. (A) Table of gene expression fold change statistics from
transcriptional profiles in primary dendritic cells from 65
individuals, before and after infection with MTB (GSE34151).
Only top 10 genes and RNF186 are shown. The rank column
refers to the rank of the gene for signal to noise ratio in the specific
study (4279 significant genes ranked). (B) Plot of RNF186 gene
expression in primary dendritic cells from 65 individuals, before
and after infection with MTB. The squares and crosses represent
median and mean respectively.
(TIFF)
Figure S13 Comparative gene expression profiling in HNF4a
mutant and control murine colons. (A) Table of gene expression
fold change statistics from comparison of transcriptional profiles in
HNF4a mutant and control murine colons (GSE3116). Only top
10 genes and RNF186 are shown. The rank column refers to the
rank of the gene for signal to noise ratio in the specific study (895
significant genes ranked). (B) Plot of RNF186 gene expression in
HNF4a mutant and control murine colons. The squares and
crosses represent median and mean respectively.
(TIFF)
Figure S14 Comparative gene expression profiling in mouse
epithelial colonswithorwithoutconditional knock outof HNF4. (A)
Table of gene expression fold change statistics from comparison of
transcriptional profiles in mouse epithelial colons with or without
conditional knock outof HNF4 (GSE11759). Onlytop 10 genesand
RNF186 are shown. The rank column refers to the rank of the gene
for signal to noise ratio in the specific study (2177 significant genes
ranked). (B) Plot of RNF186 gene expression in HNF4a conditional
knock out and control murine colons. The squares and crosses
represent median and mean respectively.
(TIFF)
Table S1 Summary of Pooled Sequencing Experiment.
(XLSX)
Table S2 Validation of high quality variants identified by
Syzygy.
(XLSX)
Table S3 Cohort descriptions.
(XLSX)
Table S4 Details of sequencing and follow-up genotyping
results, as well as association analyses for each SNP tested in this
study.
(XLSX)
Table S5 Power calculations for each SNP tested with observed
minor allele frequency greater than 0.0001.
(XLSX)
Table S6 Sequencing coverage per gene.
(XLSX)
Table S7 Table of datasets available in public domain that were
processed and analyzed for RNF186 expression.
(XLSX)
Acknowledgments
The authors would like to acknowledge the important contributions of the
Quebec IBD Genetics Consortium, the NIDDK North American IBD
Genetics Consortium and the International IBD Genetics Consortium for
sample collection and for the Immunochip genotype data used in
replication.
Members of the Quebec IBD Genetics Consortium
Guy Aumais
1, Edmond-Jean Bernard
2, Alain Bitton
3, Albert Cohen
4,
Colette Deslandres
5, Raymond Lahaie
6, Pierre Pare ´
7, John D. Rioux
8.
1H o ˆpital Maisonneuve-Rosemont, Montre ´al, Que ´bec, Canada, 2
Ho ˆpital Ho ˆtel Dieu, Montre ´al, Que ´bec, Canada, 3 Royal Victoria
Hospital, McGill University Health Centre, Montreal, Quebec, Canada,
4 Jewish General Hospital - Sir Mortimer B. Davis, Montreal, Quebec,
Canada, 5 Ho ˆpital Sainte-Justine, Montre ´al, Que ´bec, Canada, 6 CHUM –
Ho ˆpital Saint-Luc, Montre ´al, Que ´bec, Canada, 7 Centre hospitalier affilie ´
universitaire de Que ´bec – Ho ˆpital St. Sacrement, Que ´bec, Canada, 8
Universite ´ de Montre ´al and the Montreal Heart Institute Research Center,
Montre ´al, Que ´bec, Canada
Members of the NIDDK North American IBD Genetics
Consortium
Steven R Brant
1, Judy H. Cho
2, Richard H. Duerr
3, Dermot P. B.
McGovern
4, John D. Rioux
5, Mark S. Silverberg
6.
1 Johns Hopkins University School of Medicine, Department of
Medicine, and Johns Hopkins University Bloomberg School of Public
Health, Department of Epidemiology, Baltimore, Maryland, United States
of America, 2 Departments of Medicine and Genetics, Yale University,
New Haven, Connecticut, United States of America, 3 Division of
Gastroenterology, Hepatology and Nutrition, Department of Medicine,
University of Pittsburgh School of Medicine, and Department of Human
Genetics, Graduate School of Public Health, University of Pittsburgh,
Pittsburgh, Pennsylvania, United States of America, 4 Inflammatory Bowel
and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los
Angeles, California, United States of America, 5 Universite ´ de Montre ´al
and the Montreal Heart Institute Research Center, Montre ´al, Que ´bec,
Canada, 6 Mount Sinai Hospital Inflammatory Bowel Disease Group,
University of Toronto, Toronto, Ontario, Canada
Members of the International Inflammatory Bowel Disease
Genetics Consortium
Tariq Ahmad
6, Carl A. Anderson
3, Vito Annese
15,64, Robert N.
Baldassano
20, Tobias Balschun
8, Murray Barclay
10, Jeffrey C. Barrett
3,
Theodore M. Bayless
21, Joshua C. Bis
11, Stephan Brand
22, Steven R.
Brant
21, Suzanne Bumpstead
3, Carsten Buning
23, Judy H. Cho
19,63, Albert
Cohen
24, Jean-Frederick Colombel
25,M a r i oC o t t o n e
26,M a u r o
D’Amato
57, Renata D’Inca
29, Mark J. Daly
65, Ted Denson
27, Marla
Dubinsky
30, Richard H. Duerr
47,61, Cathryn Edwards
31, David Ellin-
ghaus
1, Tim Florin
32, Denis Franchimont
33, Andre Franke
1, Richard
Gearry
10, Michel Georges
13, Jurgen Glas
22,34,35, Andre Van Gossum
33,
Anne M. Griffiths
55, Stephen L. Guthery
36, Hakon Hakonarson
4,20, Talin
Haritunians
14, Jean-Pierre Hugot
39, Dirk J de Jong
66, Luke Jostins
3, Subra
Deep Resequencing of GWAS Loci in UC
PLOS Genetics | www.plosgenetics.org 9 September 2013 | Volume 9 | Issue 9 | e1003723Kugathasan
59, Gerd Kullak-Ublick
54, Anna Latiano
15, Debby Laukens
28,
Ian Lawrance
40, James Lee
9, Charlie W. Lees
7, Marc Lemann
41, Arie
Levine
42, Cecile Libioulle
43, Edouard Louis
43, John C. Mansfield
60,
Christopher G. Mathew
16, Dermot P.B. McGovern
2,14, Mitja Mitro-
vic
12,67, Grant W. Montgomery
17, Craig Mowat
44, William Newman
45,
Orazio Palmieri
15, Julia ´n Pane ´s
46, Miles Parkes
9, Anne Phillips
44, C.Y.
Ponsioen
52, Uros Potocnik
67, Natalie J. Prescott
16, Deborah D. Proctor
19,
Graham L. Radford-Smith
5, Miguel Regueiro
47, John D. Rioux
56,
Rebecca Roberts
10,J e r o m eI .R o t t e r
14, Paul Rutgeerts
48,J e r e m y
Sanderson
49, Miquel Sans
46, Jack Satsangi
7, Stefan Schreiber
1,62, Philip
Schumm
18, Frank Seibold
50, Yashoda Sharma
19, Mark S. Silverberg
51,
Lisa A. Simms
5, A. Hillary Steinhart
51, Stephan R. Targan
2, Kent D.
Taylor
14, Leif Torkvist
53, Severine Vermeire
48, Jonas Halfvarson
37, H.W.
Verspaget
38, Martine De Vos
28, Thomas Walters
55, Kai Wang
4, Rinse K.
Weersma
58, David Whiteman
17, Cisca Wijmenga
12.
1 Institute of Clinical Molecular Biology, Christian-Albrechts-University
Kiel, Kiel, Germany, 2 Inflammatory Bowel and Immunobiology
Research Institute, Cedars-Sinai Medical Center, Los Angeles, California,
USA, 3 Wellcome Trust Sanger Institute, Wellcome Trust Genome
Campus, Hinxton, Cambridge, UK, 4 Center for Applied Genomics, The
Children’s Hospital of Philadelphia, Philadelphia, USA, 5 Inflammatory
Bowel Disease Research Group, Queensland Institute of Medical
Research, Brisbane, Australia, 6 Peninsula College of Medicine and
Dentistry, Barrack Road, Exeter, UK, 7 Gastrointestinal Unit, Molecular
Medicine Centre, University of Edinburgh, Western General Hospital,
Crewe Road, Edinburgh, UK, 8 popgen Biobank, Christian-Albrechts
University Kiel, Kiel, Germany, 9 Gastroenterology Research Unit,
Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK, 10
Department of Medicine, University of Otago, Christchurch, New
Zealand, 11 Cardiovascular Health Research Unit, Department of
Medicine, University of Washington, Seattle, USA, 12 Department of
Genetics, University Medical Center Groningen, Groningen, the Nether-
lands, 13 Department of Genetics, Faculty of Veterinary Medicine,
University of Lie `ge, Lie `ge, Belgium, 14 Medical Genetics Institute, Cedars-
Sinai Medical Center, Los Angeles, California, USA, 15 Unit of
Gastroenterology, IRCCS-CSS Hospital, San Giovanni Rotondo, Italy,
16 Department of Medical and Molecular Genetics, King’s College
London School of Medicine, Guy’s Hospital, London, UK, 17 Molecular
Epidemiology, Queensland Institute of Medical Research, Brisbane,
Australia, 18 Department of Health Studies, University of Chicago,
Chicago, Illinois, USA, 19 Section of Digestive Diseases, Department of
Medicine, Yale University, New Haven, Connecticut, USA, 20 Depart-
ment of Pediatrics, Center for Pediatric Inflammatory Bowel Disease, The
Children’s Hospital of Philadelphia, Philadelphia, USA, 21 Inflammatory
Bowel Disease Center, Dept. of Medicine, Johns Hopkins University
School of Medicine, Baltimore, Maryland, USA, 22 Department of
Medicine II, University Hospital MunichGrosshadern, Ludwig-Maximi-
lians University, Munich, Germany, 23 Department of Gastroenterology,
Charite ´, Campus Mitte, Universita ¨tsmedizin Berlin, Berlin, Germany, 24
Montreal Jewish General Hospital, Montre ´al, Que ´bec, Canada, 25
Registre EPIMAD, Universite ´ de Lille, Lille, France, 26 Unit of
Gastroenterology, Cervello Hospital, Palermo, Italy, 27 Pediatric Gastro-
enterology, Cincinnati Children’s Hospital. Medical Center, Cincinnati,
USA, 28 Department of Hepatology and Gastroenterology, Ghent
University Hospital, Ghent, Belgium, 29 Division of Gastroenterology,
University Hospital Padua, Italy, 30 Department of Pediatrics, Cedars
Sinai Medical Center, Los Angeles, CA, USA, 31 Torbay Hospital,
Torbay, Devon, UK, 32 Department of Gastroenterology, Mater Health
Services, Brisbane, Australia, 33 Department of Gastroenterology,
Erasmus Hospital, Free University of Brussels, Brussels, Belgium, 34
Department of Preventive Dentistry and Periodontology, Ludwig-Max-
imilians University, Munich, Germany, 35 Department of Human
Genetics, RWTH Aachen, Germany, 36 Department of Pediatrics,
University of Utah School of Medicine, Salt Lake City, UT, USA, 37
Department of Medicine, O ¨ rebro University Hospital, O ¨ rebro, Sweden, 38
Dept of Gastroenterology, Leiden University Medical Center, Leiden, The
Netherlands, 39 Universite ´ Paris Diderot, Paris, France, 40 School of
Medicine and Pharmacology, The University of Western Australia,
Fremantle, Australia, 41 GETAID group, Universite ´ Paris Diderot, Paris,
France, 42 Pediatric Gastroenterology Unit, Wolfson Medical Center and
Sackler School of Medicine, Tel Aviv University, Israel, 43 Division of
Gastroenterology, CHU, Universite ´ de Lie `ge, Lie `ge, Belgium, 44 Dept of
Medicine, Ninewells Hospital and Medical School, Dundee, UK, 45
Department of Medical Genetics, University of Manchester, Manchester,
UK, 46 Department of Gastroenterology, Hospital Clı ´nic/IDIBAPS.
CIBER EHD. Barcelona, Spain, 47 Division of Gastroenterology,
Hepatology and Nutrition, School of Medicine, University of Pittsburgh,
Pittsburgh, Pennsylvania, USA, 48 Division of Gastroenterology, Univer-
sity Hospital Gasthuisberg, Leuven, Belgium, 49 Dept Gastroenterology,
Guy’s & St Thomas’ NHS Foundation Trust, St Thomas’ Hospital,
London, UK, 50 Division of Gastroenterology, Inselspital, University of
Bern, Bern, Switzerland, 51 Mount Sinai Hospital Inflammatory Bowel
Disease Centre, University of Toronto, Canada, 52 Department of
Gastroenterology, Academic Medical Center, Amsterdam, the Nether-
lands, 53 Department of Clinical Science Intervention and Technology,
Karolinska Institutet, Stockholm, Sweden, 54 Division of Clinical
Pharmacology and Toxicology University Hospital Zurich, Zurich,
Switzerland, 55 The Hospital for Sick Children, University of Toronto,
Ontario, Canada, 56 Universite ´ de Montre ´al and the Montreal Heart
Institute, Research Center, Montre ´al, Que ´bec, Canada, 57 Department of
Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden, 58
Department of Gastroenterology, University Medical Center Groningen,
Groningen, The Netherlands, 59 Department of Pediatrics; Emory
University School of Medicine, Atlanta, GA, USA, 60 Institute of Human
Genetics, Newcastle University, Newcastle upon Tyne, UK, 61 Depart-
ment of Human Genetics, Graduate School of Public Health, University of
Pittsburgh, Pittsburgh, Pennsylvania, USA, 62 Department for General
Internal Medicine, Christian-Albrechts-University, Kiel, Germany, 63
Department of Genetics, Yale School of Medicine, New Haven CT, USA,
64 Unit of Gastroenterology, University Hospital Careggi Florence, Italy,
65 Center for Human Genetic Research, Massachusetts General Hospital,
Harvard Medical School, Boston, Massachusetts, USA, 66 Department of
Gastroenterology and Hepatology, Radboud University Medical Center
Nijmegen, the Netherlands, 67 University of Maribor, Faculty of Medicine,
Center for human molecular genetics and pharmacogenomics, Maribor,
Slovenia
Author Contributions
Conceived and designed the experiments: PG GL MJD JDR. Analyzed the
data: PG MB GB KSL GG. Wrote the paper: MB PG GB MAR RJX
MJD JDR. Functional characterization design and coordination: GG JB
RJX. Study subject recruitment and phenotyping: AB SRB FB RHD JHC
DPBM GRS SS MSS JH VA RKW MD SV AF JDR RJX LT. Sequenom
assay designs: PG MB AA CL. Pooled sequencing protocol was design at
the Broad Institute: MAR CS MJD. Pooling and sequencing protocol at
the Montreal Heart Institute: MB. Follow-up genotyping: AA CL CS DE
MB. Supplied follow-up genotyping data: MD SV MJD AF RKW. Data
management for NIDDK IBDGC and IIBDGC Immunochip, and sample
management for follow-up genotyping from the NIDDK IBDGC: YS PLS.
Targeted exon capture design: KSL. Preparation and clean-up of primary
sequence data and bioinformatic support: KSL. Designed the statistical
and computational analyses: MAR MJD. Performed the statistical and
computational analyses: PG ML GB. Project management: PG GL RJX
JDR MJD. Supervised all aspects of the study: JDR.
References
1. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory
bowel disease. Nature 448: 427–434.
2. Anderson CA, Boucher G, Lees CW, Franke A, D’Amato M, et al. (2011) Meta-
analysis identifies 29 additional ulcerative colitis risk loci, increasing the number
of confirmed associations to 47. Nat Genet 43: 246–252.
3. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, et al. (2012) Host-
microbe interactions have shaped the genetic architecture of inflammatory
bowel disease. Nature 491: 119–124.
4. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, et al. (2006) A
genome-wide association study identifies IL23R as an inflammatory bowel
disease gene. Science 314: 1461–1463.
5. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, et al. (2007)
Genome-wide association study identifies new susceptibility loci for Crohn disease
and implicates autophagy in disease pathogenesis. Nat Genet 39: 596–604.
6 .H a m p eJ ,F r a n k eA ,R o s e n s t i e lP ,T i l lA ,T e u b e rM ,e ta l .( 2 0 0 7 )A
genome-wide association scan of nonsynonymous SNPs identifies a
Deep Resequencing of GWAS Loci in UC
PLOS Genetics | www.plosgenetics.org 10 September 2013 | Volume 9 | Issue 9 | e1003723susceptibility variant for Crohn disease in ATG16L1. Nature Genetics 39:
207–211.
7. Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, et al. (2011) Deep
resequencing of GWAS loci identifies independent rare variants associated with
inflammatory bowel disease. Nat Genet 43: 1066–1073.
8. McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, et al. (2010) Genome-
wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet
42: 332–337.
9. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, et al. (2008) Genome-
wide association defines more than 30 distinct susceptibility loci for Crohn’s
disease. Nat Genet 40: 955–962.
10. Festen EA, Goyette P, Scott R, Annese V, Zhernakova A, et al. (2009) Genetic
variants in the region harbouring IL2/IL21 associated with ulcerative colitis.
Gut 58: 799–804.
11. Momozawa Y, Mni M, Nakamura K, Coppieters W, Almer S, et al. (2011)
Resequencing of positional candidates identifies low frequency IL23R coding
variants protecting against inflammatory bowel disease. Nat Genet 43: 43–47.
12. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010)
A method and server for predicting damaging missense mutations. Nat Methods
7: 248–249.
13. Williams IR (2004) Chemokine receptors and leukocyte trafficking in the
mucosal immune system. Immunol Res 29: 283–292.
14. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, et al. (2007) Genetic
variants regulating ORMDL3 expression contribute to the risk of childhood
asthma. Nature 448: 470–473.
15. Natoli G, Chiocca S (2008) Nuclear ubiquitin ligases, NF-kappaB degradation,
and the control of inflammation. Science signaling 1: pe1.
16. Zhao W, Wang L, Zhang M, Yuan C, Gao C (2012) E3 Ubiquitin Ligase
Tripartite Motif 38 Negatively Regulates TLR-Mediated Immune Responses by
Proteasomal Degradation of TNF Receptor-Associated Factor 6 in Macrophag-
es. J Immunol 188: 2567–2574.
17. Jin W, Chang M, Sun SC (2012) Peli: a family of signal-responsive E3 ubiquitin
ligases mediating TLR signaling and T-cell tolerance. Cell Mol Immunol 9:
113–122.
18. Fernandez MI, Regnault B, Mulet C, Tanguy M, Jay P, et al. (2008) Maturation
of paneth cells induces the refractory state of newborn mice to Shigella infection.
J Immunol 180: 4924–4930.
19. Li X, Madison BB, Zacharias W, Kolterud A, States D, et al. (2007)
Deconvoluting the intestine: molecular evidence for a major role of the
mesenchyme in the modulation of signaling cross talk. Physiol Genomics 29:
290–301.
20. Boyd M, Bressendorff S, Moller J, Olsen J, Troelsen JT (2009) Mapping of
HNF4alpha target genes in intestinal epithelial cells. BMC Gastroenterol 9: 68.
21. Fang B, Mane-Padros D, Bolotin E, Jiang T, Sladek FM (2012) Identification of
a binding motif specific to HNF4 by comparative analysis of multiple nuclear
receptors. Nucleic Acids Res 40: 5343–5356.
22. Ktistaki E, Talianidis I (1997) Modulation of hepatic gene expression by
hepatocyte nuclear factor 1. Science 277: 109–112.
23. Kyrmizi I, Hatzis P, Katrakili N, Tronche F, Gonzalez FJ, et al. (2006) Plasticity
and expanding complexity of the hepatic transcription factor network during
liver development. Genes Dev 20: 2293–2305.
24. Tomaru Y, Nakanishi M, Miura H, Kimura Y, Ohkawa H, et al. (2009)
Identification of an inter-transcription factor regulatory network in human
hepatoma cells by Matrix RNAi. Nucleic Acids Res 37: 1049–1060.
25. Bandyopadhyay S, Chiang CY, Srivastava J, Gersten M, White S, et al. (2010) A
human MAP kinase interactome. Nat Methods 7: 801–805.
26. Das D, Nahle Z, Zhang MQ (2006) Adaptively inferring human transcriptional
subnetworks. Mol Syst Biol 2: 2006 0029.
27. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, et al. (2004)
Control of pancreas and liver gene expression by HNF transcription factors.
Science 303: 1378–1381.
28. Garrison WD, Battle MA, Yang C, Kaestner KH, Sladek FM, et al. (2006)
Hepatocyte nuclear factor 4alpha is essential for embryonic development of the
mouse colon. Gastroenterology 130: 1207–1220.
29. Darsigny M, Babeu JP, Dupuis AA, Furth EE, Seidman EG, et al. (2009) Loss of
hepatocyte-nuclear-factor-4alpha affects colonic ion transport and causes
chronic inflammation resembling inflammatory bowel disease in mice. PLoS
One 4: e7609.
30. Marcil V, Seidman E, Sinnett D, Boudreau F, Gendron FP, et al. (2010)
Modification in oxidative stress, inflammation, and lipoprotein assembly in
response to hepatocyte nuclear factor 4alpha knockdown in intestinal epithelial
cells. J Biol Chem 285: 40448–40460.
31. Goyette P, Lefebvre C, Ng A, Brant SR, Cho JH, et al. (2008) Gene-centric
association mapping of chromosome 3p implicates MST1 in IBD pathogenesis.
Mucosal Immunol 1: 131–138.
32. Asano K, Matsushita T, Umeno J, Hosono N, Takahashi A, et al. (2009) A
genome-wide association study identifies three new susceptibility loci for
ulcerative colitis in the Japanese population. Nat Genet 41: 1325–1329.
33. Dassopoulos T, Nguyen GC, Bitton A, Bromfield GP, Schumm LP, et al. (2007)
Assessment of reliability and validity of IBD phenotyping within the National
Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD
Genetics Consortium (IBDGC). Inflamm Bowel Dis 13: 975–983.
34. Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, et al. (2008)
Genetic determinants of ulcerative colitis include the ECM1 locus and five loci
implicated in Crohn’s disease. Nat Genet 40: 710–712.
35. Brown AM, Lo KS, Guelpa P, Beaudoin M, Rioux JD, et al. (2010) Optimus
Primer: A PCR enrichment primer design program for next-generation
sequencing of human exonic regions. BMC Res Notes 3: 185.
36. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, et al. (2009) Solution
hybrid selection with ultra-long oligonucleotides for massively parallel targeted
sequencing. Nat Biotechnol 27: 182–189.
37. Li H, Ruan J, Durbin R (2008) Mapping short DNA sequencing reads and
calling variants using mapping quality scores. Genome Res 18: 1851–1858.
38. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The
Genome Analysis Toolkit: a MapReduce framework for analyzing next-
generation DNA sequencing data. Genome Res 20: 1297–1303.
39. Caja L, Bertran E, Campbell J, Fausto N, Fabregat I (2011) The transforming
growth factor-beta (TGF-beta) mediates acquisition of a mesenchymal stem cell-
like phenotype in human liver cells. J Cell Physiol 226: 1214–1223.
40. Hong MH, Chou YC, Wu YC, Tsai KN, Hu CP, et al. (2012) Transforming
growth factor-beta1 suppresses hepatitis B virus replication by the reduction of
hepatocyte nuclear factor-4alpha expression. PLoS One 7: e30360.
41. Wang B, Cai SR, Gao C, Sladek FM, Ponder KP (2001) Lipopolysaccharide
results in a marked decrease in hepatocyte nuclear factor 4 alpha in rat liver.
Hepatology 34: 979–989.
42. Boyd M, Hansen M, Jensen TG, Perearnau A, Olsen AK, et al. (2010) Genome-
wide analysis of CDX2 binding in intestinal epithelial cells (Caco-2). J Biol Chem
285: 25115–25125.
43. McKinney-Freeman SL, Lengerke C, Jang IH, Schmitt S, Wang Y, et al. (2008)
Modulation of murine embryonic stem cell-derived CD41+c-kit+ hematopoietic
progenitors by ectopic expression of Cdx genes. Blood 111: 4944–4953.
Deep Resequencing of GWAS Loci in UC
PLOS Genetics | www.plosgenetics.org 11 September 2013 | Volume 9 | Issue 9 | e1003723